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Abstract Several point mutations in mitochondrial tRNA genes 
have been linked to distinct clinical subgroups of mitochondrial 
diseases. A particularly large number of different mutations is 
found in the tRNA Leu(UuR) gene. We show that base substitu- 
tions at nucleotide position 3256, 3260, and 3271 of the 
mitochondrial genome, located in the D and anticodon stem of 
this tRNA, and mutation 3243 changing a base involved in a 
tertiary interaction, significantly impair the processing of the 
tRNA precursor in vitro. In correlation with other studies, our 
results suggest that inefficient processing of certain mutant 
variants of mitochondrial tRNA L~u(UUR) is a primary molecular 
impairment leading to mitochondrial dysfunction and conse- 
quently to disease. 
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1. Introduction 
Mitochondrial diseases are a diverse group of clinical con- 
ditions defined by mitochondrial dysfunction [1]. Hence, 
although essentially multisystemic, they are predominantly 
manifested as encephalomyopathies. In the past years several 
mutations (mainly base substitutions, large scale deletions and 
duplications) in mtDNA have been linked to distinct clinical 
subgroups of mitochondrial encephalomyopathies and thereby 
pushed research on the pathogenesis of this heterogeneous 
group of disorders (for reviews, see [2 5]). tRNA genes appear 
to be particularly frequently affected by such mutations. How- 
ever, the actual molecular consequences of these base substi- 
tutions with respect o tRNA structure and function are still 
largely unclear, and so is the molecular pathology. Since in 
vivo studies are complicated by a varying degree of hetero- 
plasmy, variable nuclear genetic background, and limited by 
the availability of biopsy material, most approaches have used 
a cell culture system designed for the analysis of mtDNA 
mutations to study the molecular pathology of the associated 
diseases [(>8]. These studies revealed that tRNA base substi- 
tutions cause a generalized impairment of mitochondrial pro- 
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tein synthesis and consequently a decrease in oxidative phos- 
phorylation capacity [7-14]. More specifically, in one case a 
decreased aminoacylation of the affected tRNA was found 
[15], and in two other cases the specific accumulation of the 
tRNA precursor [8,16]. Furthermore, in some cases the 
steady-state l vel of the affected tRNA was decreased [12 
15]. Yet, complementing research, using in vitro systems 
with their inherent advantage to directly address potential 
underlying molecular mechanisms, has not been carried out. 
The recent development of a human mitochondrial in vitro 
tRNA processing system that faithfully reflects the in vivo 
processing event enables to analyze the effect of mutations 
in tRNA genes on this critical step in mitochondrial biogen- 
esis [17]. Notably, mammalian mitochondrial tRNAs are 
made together with rRNA and mRNA genes as large poly- 
cistronic primary transcripts. Within these, the tRNAs act as 
recognition signals for endonucleases, RNase P and 3' pre- 
tRNase, cleaving precisely at the 5' and 3' ends of the tRNAs 
[17], and thus, due to the unique genetic arrangement [18], 
releasing tRNAs, rRNAs, and mRNAs as a natural conse- 
quence of tRNA processing [19]. Alterations, qualitatively 
or quantitatively, will therefore not only affect the respective 
tRNA, but also the immediately adjacent RNAs and more- 
over generate unusual (levels of) precursor RNA species. In 
this paper the processing efficiency and specificity of wild-type 
and mutant, disease-associated precursors of 
(mt)tRNA I~''~i~:vm are compared using the aforementioned 
in vitro system. Whilst none of the 12 base substitutions 
studied changes the specificity of the processing reaction, a 
severe decrease in the processing rate of certain mutant pre- 
cursors was observed. The quantitative r sults of 5' end proc- 
essing by mtRNase P are furthermore compared to the data 
obtained for the same mutant RNA precursors with nRNase 
P, and provide novel aspects for the understanding of RNase 
P substrate recognition. 
2. Materials and methods 
2.1. Precursor tRNA substrates 
phL, the template for in vitro transcription of wild-type (mt)pre- 
tRNA 1*"/tr~ I~l, has previously been described indetail [17]. The differ- 
ent point-mutant substrate t mplates were derived from phL by PCR 
mutagenesis e sentially as described [20]. The sequence of the com- 
plete transcribed region of each plasmid was confirmed by dideoxy 
sequencing (T7 Sequencing kit, Pharmacia). Plasmids were cleaved 
with restriction endonuclease RsaI prior to transcription with bacter- 
iophage T3 RNA polymerase. In vitro transcription reactions con- 
tained 80 mM HEPES-KOH (pH 7.6), 12 mM MgCl,, 2 mM spermi- 
dine, 40 mM dithiothreitol, 500 BM each of ATP, CTP, and UTP, 150 
mM GTP, 5 p.Ci [~-a2P]GTP to achieve the desired specific activity, 
1 unit/Bl rRNasin (Promega), 5 units/ml yeast inorganic pyrophospha- 
tase (Sigma), 1 unit/Bl RNA polymerase, and 50 gg/ml template 
DNA. Transcripts were purified by denaturing polyacrylamide g l 
electrophoresis. 
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2.2. Preparation of tRNA processing enzymes 
Mitochondrial tRNA processing activities (mtRNase P and rot3' 
pre-tRNase) were prepared by PEG precipitation and glycerol gra- 
dient sedimentation asrecently described [21]. 
nRNase P was prepared as previously described [17]. 
2.3. Processing assays 
Processing reactions were carried out as previously described [17]. 
The substrate concentration was 10 nM. Enzymes and substrate were 
preincubated separately under reaction conditions. The reactions were 
started by mixing enzyme and substrate, and aliquots were withdrawn 
at different imes. Reactions were stopped and analyzed by denaturing 
polyacrylamide gel electrophoresis a previously described [17]. Un- 
processed precursor and processing products were quantitated from 
polyacrylamide gels using a PhosphorImager and ImageQuant soft- 
ware (Molecular Dynamics). The relative initial cleavage rates of dif- 
ferent substrates (product formation per given time interval relative to 
product formation from wild-type substrate) were deduced from linear 
ranges of curves. 
3. Results 
3.1. Point mutations in (mt)tRNALeu(UUR) 
Eleven base substitution mutations within the 
(mt)tRNA b~"(UUa) gene have been reported to date. With 10 
of these associated with mitochondrial  disease, the 
(mt)tRNA L~''(vUR) gene not only exhibits the largest number 
of presumably pathogenic mutat ions within a localized region 
of the mtDNA,  but also roughly as many mutat ions as the 
remaining 21 tRNA genes together. Fig. 1 and Table 1 display 
all these mutat ions and their position in the mitochondrial  
genome [18], and this position number will be used through- 
out this report when referring to a specific mutation. (Note: 
while this study was in progress, two further mutat ions asso- 
ciated with mitochondrial  encephalomyopathy, the deletion of 
nucleotide 3272 and an A to T transversion at position 3243, 
were reported [22,23].) 
The base substitutions were introduced in a previously de- 
scribed precursor for (mt)tRNA L~'(UUR) [17] by in vitro muta- 
genesis. Sequencing of the mutagenized template plasmids en- 
sured that the in vitro transcribed precursors did not contain 
any other mutat ion than the desired one. Fig. 1 schematically 
displays the tRNA precursor and all the base substitutions. In 
addition to the 11 mutat ions described, an A at position 3266 
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Fig. 1. Schematic display of the precursor for mitochondrial 
tRNA u~u(vUl~). The sequence of (mt)tRNA L~/tJUr~i s embedded be- 
tween the 16S rRNA and the NADH dehydrogenase ubunit 1 
mRNA (ND 1) in the primary transcript. The in vitro transcribed 
precursor starts with 35 nucleotides of polylinker sequence, followed 
by the 12 3' terminal nucleotides of 16S rRNA, the tRNA L~"(UUR), 
and terminates at an RsaI restriction site 34 nucleotides down- 
stream, within the ND 1 mRNA [17]. The 11 reported transitions 
are within circles (see also Table 1), and identified by their nucleo- 
tide position in the mitochondrial genome [18]. The A to G transi- 
tion in the anticodon, included in this study as a control, is within 
a box. Arrows mark the exact cleavage sites. 
was replaced by a G as a further control (Fig. 1, Table 1). 
This substitution changes the anticodon from UAA to UGA,  
normally found in (mt)tRNA s~r(Uc~'). A similar ant icodon 
swap in (mt)tRNA pr° has been reported in a patient with 
mitochondrial  myopathy [24]. 
3.2. Processing of mutant RNA precursors by mitochondrial 
enzymes 
The different mutant  tRNA precursors were analyzed in 
parallel to the wild-type using a previously characterized in 
vitro processing system [17]. Crude mitochondrial  extracts 
(data not shown) as well as partially purified mtRNase P 
and mt3' pre-tRNase were employed (Fig. 2, Table 1), though 
the relative cleavage rates did not change upon purification of 
Table 1 
Processing of mutant precursors for mitochondrial tRNA u''lCUUL~/ 
Nucleotide position Base sub- Key Associated clinical Relative efficiency of Relative processing Relative processing 
in mtDNA (tRNA) a stitution reference phenotype b (remarks) tRNA formation ~' efficiency (mtRNase P)~t efficiency (nRNase P)' 
3230-3304 none [18]  wild-type 100 
3243 (14) A ~ G [48 ,49]  MELAS, PEO, diabetes 19 + 5 
3250 (20) T~C [50]  myopathy 68_+5 
3251 (20a) A~G [51]  myopathy 42+6 
3252 (21 ) A ---, G [52]  encephalomyopathy 38 + 4 
3254 (23) C ~ T [53] ? (natural polymorphism) 83 _+ 13 
3256 (25) C--, T [46]  multisystem, MELAS not determined 
3260 (29) A ~ G [54]  cardiomyopathy, 29 _+ 1 
myopathy 
3266 (35) A~G ? (control, anticodon) 89_+6 94_+8 116+8 
3271 (40) T~C [55] MELAS 20+6 16_+4 138_+6 
3291 (60) T---, C [56] MELAS 74_+3 79_+4 193+ 19 
3302 (71) A ---, G [40]  myopathy 65_+6 74_+4 119+4 
3303 (72) C--*T [57]  cardiomyopathy 66+5 71 _+4 217_+9 
100 100 
19+9 76+2 
63 + 6 88 + 22 
53_+7 86_+11 
47_+3 138_+28 
92_+8 50_+6 
4_+4 119_+21 
28_+3 164_+25 
~According to [18] and [58], respectively. 
~'MELAS, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like pisodes; PEO, progressive external ophthalmoplegia. 
q%) relative to wild-type, determined as described in Section 2; mean + S.D. (3-5 experiments). 
~i(%) release of 5' leader relative to wild-type, determined as described in Section 2: mean + S,D. (4-6 experiments). 
~(%) release of 5' leader relative to wild-type, determined as described in Section 2; mean + S.D. (3 experiments). 
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Fig. 2. Processing of mutant RNA precursors by mitochondrial enzymes. The wild-type precursor for (mt)tRNA L~'<w'm and the mutant deriv- 
atives, as indicated above each lane (compare Fig. 1 and Table 1 for identification), were incubated in parallel with mtRNase P and (mt)pre- 
tRNA Y-endonuclease under the previously described conditions [17]. The cleavage products were analyzed by denaturing polyacrylamide g l 
electrophoresis (6% gel) and autoradiography. An early kinetic time-point is shown (6 min). Substrate and cleavage products are schematically 
drawn on the right. The trailer product is not visible on this exposure because of its relative lower labeling intensity. Note: The two additional 
RNA species of 61 and 95 nucleotides in length, present only in lane 1 (mutant 3243), are not due to aberrant processing, but were consistently 
observed in all batches of this very substrate, ven after successive rounds of gel purification of the substrate RNA. The significance of these 
breakdown products is not known, nor has it been investigated, They are, however, neither dependent on nor affected by the addition of mito- 
chondrial enzyme preparations to the substrate RNA, but are present from the very beginning in the substrate preparation, i.e. their size and 
amount are not detectably altered while cleavage reactions are carried out. 
the enzymes. The mitochondrial enzyme preparations were 
furthermore verified not to contain any contaminating 
nRNase P using the Escherichia coli pre-tRNATY"su~ + sub- 
strate [17] and by RNase protection analysis for H1 RNA, 
the RNA component of nRNase P (data not shown). 
No qualitative processing alterations were observed with 
any of the studied mutant RNA precursors. None of the 12 
base substitutions affected cleavage site selection of either 
mtRNase P (5' cleavage) or mt3' pre-tRNase (3' cleavage); 
the respective cleavage products of mutant substrates had ex- 
actly the same size as those of the wild-type (Fig. 2). However, 
considerable alterations in the processing rates of distinct mu- 
tant tRNA precursors were observed (Table 1, Fig. 2). Hence, 
the relative efficiency of tRNA formation and the relative 
processing efficiency at the tRNA 5' end (cleavage by 
mtRNase P) were quantitatively determined (Table 1). The 
C to T transition 3256, at the base of the D stem, had the 
most striking effect on processing, as the cleavage rate by 
mtRNase P was decreased more than 20-fold, and did not 
allow to determine the efficiency of tRNA formation. Base 
substitutions at 3243, 3260, and 3271 also showed a pro- 
nounced (approximately fivefold) decrease in their ability to 
serve as a substrate for mtRNase P, and the relative efficiency 
of tRNA formation was reduced roughly to the same extent 
with these mutants. Yet, the remaining mutants (3250, 3251, 
3252, 3291, 3302, 3303) did not markedly affect susceptibility 
to cleavage by mtRNase P, or overall tRNA formation. Re- 
duction in processing efficiency was either approximately two- 
fold (3250, 3251, 3252), or less (3291, 3302, 3303). Mutant 
precursors 3254, presumably a neutral polymorphism, and 
3266, an A to G transition in the anticodon, were cleaved 
at a rate similar to that of the wild-type. 
Taken together, these results demonstrate that certain 
disease associated point mutations in the human 
(mt)tRNA L~'u(U~a) gene have a profound quantitative ffect 
on the processing of the tRNA precursor, but do not lead 
to aberrant processing products. In addition to their patho- 
biological relevance these data may furthermore point to spe- 
cific structural features of (mt)tRNAs involved in recognition 
by mitochondrial tRNA processing enzymes (see below). 
3.3. Processing o f  mutant mitochondrial tRNA precursors by 
nuclear RNase P 
Apart from the first studies concerning substrate specificity 
of human mtRNase P [17], no data about substrate recogni- 
tion by vertebrate mitochondrial tRNA processing enzymes 
were available as yet. By way of contrast, substrate recogni- 
tion by vertebrate nRNase P has been extensively studied in 
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recent years [25 28]. Cleavage analysis of the described mu- 
tant (mt)tRNA precursors by nRNase P, although likely of no 
relevance for the in vivo/in mitochondrion situation, should 
thus help to evaluate the results obtained with mtRNase P as 
well as to understand the commonalities and diversities of 
these two cellular RNase P enzymes. 
Experiments were carried out essentially in the same way as 
with mtRNase P. Again, the cleavage site was not changed 
(data not shown). But in sharp contrast to mtRNase P, 
nRNase P was not markedly affected in its ability to cleave 
any of the mutant substrate RNAs (Table 1). Cleavage rates 
ranged from a twofold decrease to a twofold increase relative 
to the wild-type substrate. Still, there was no correlation in 
these alterations to those obtained with mtRNase P, thereby 
confirming the previous notion that substrate requirements of 
mtRNase P and nRNase P are different [17,29]. 
4. Discussion 
4.1. tRNA structure and tRNA processing 
Mutation 3254, presumably a neutral polymorphism, gen- 
erates an A-U base pair found in other vertebrates at this 
position. This 'strengthening' of the D stem does not alter 
the processing rate of the precursor. Similarly, changing the 
anticodon of a tRNA (control mutation 3266) is not expected 
to affect tRNA structure and processing. Mutations in 
(mt)tRNA L''''/UvR) that have a pronounced effect on the proc- 
essing of its precursor, on the other hand, change bases con- 
served throughout vertebrate volution (3243, 3256, 3260) 
and/or likely involved in stabilizing a stem structure (3256, 
3260, 3271) or tertiary conformation (3243). In this context 
it is important o note that the D and anticodon stem of 
(mt)tRNA I'''''i~t:R) appear to be rather weakly stabilized struc- 
tures, and might thus be more prone to alterations leading to 
structural disturbances. The anticodon stem is composed of 
four A-U base pairs and a terminal A C mismatch (Fig. 1). 
Mutation 3271 introduces a second A C mismatch, and A to 
G transition 3260 generates the weaker G-U base interaction. 
Both have a considerable quantitative effect on processing, 
but that of the more severe alteration (3271) is more pro- 
nounced. 
The D stem of (mt)tRNA L~'"!vH~), although formed at its 
base by two G-C base pairs, is closed against he loop by a 
G.U following an unpaired A C (Fig. 1). Mutation 3256, 
which has the most striking effect on the processing rate, 
generates a G-U instead of the first G-C and might thereby 
significantly weaken the D stem. The T and acceptor stem of 
(mt)tRNA L''l'!rt~R) are, in contrast, stabilized by standard 
"Watson-Crick' base pairing over their entire length. This 
might explain why mutation 3302 and 3303, both of which 
generate a non-canonical G.U base pair, have only a very 
moderate ffect on precursor processing. 
The A3243 at tRNA position 14, an invariant nucleotide 
among bacterial and cytoplasmic tRNAs [30], is hydrogen 
bonded to U8 according to the X-ray crystal structure of yeast 
tRNA P~'', and contributes to the stabilization of tRNA terti- 
ary structure [31]. This nucleotide pair is present in all known 
vertebrate (mt)tRNAs L'''~/UU~i, though some other (mt)tRNAs 
apparently lack this very tertiary interaction [30,32]. The fre- 
quently found A to G transition 3243 may nevertheless ig- 
nificantly affect the three-dimensional structure of 
(mt)tRNA L'''~iUl ~i, the vertebrate (mt)tRNA most similar to 
'classical' tRNA structures [18,30], and hence the processing 
of its precursor. 
The remaining base substitutions (3250, 3251, 3252, 3291), 
which do not extraordinarily alter processing rates, concern 
nucleotides not conserved in vertebrate evolution, and, except 
for 3252, have not previously been implicated with higher 
order tRNA structure. A3252 at position 21 in the tRNA is 
involved in a triple interaction with the aforementioned US- 
A14 base pair in the yeast tRNA Ph~ model [30,3l]. 
The overall rate of tRNA formation in vitro for all the 
different mutants follows more or less the relative cleavage 
rate at the 5' end. Nevertheless this does not allow us to 
conclude that 3' end processing is not affected by the muta- 
tions, since this study was not designed to analyze a possible 
quantitative effect on 3' end cleavage. The results obtained for 
5' end processing by mtRNase P, however, can be compared 
to the data obtained with nRNase P. Interestingly, the struc- 
tural alterations caused by the studied mutations are restricted 
to the D domain and the anticodon stem, both apparently 
more important for substrate recognition and cleavage by 
mtRNase P than by nRNase P. The recent identification of 
the unique processing pathway of human (mt)tRNA s'~/A(~vl, a 
tRNA with an abnormal anticodon stem and lacking a D 
domain, previously indicated the critical importance of both 
features for processing by mtRNase P [29]. For catalysis by 
human nRNase P on the other hand, the length of the accept- 
or stem as well as the structure of the T domain have previ- 
ously been identified as critical elements [25,26]. While the 
latter is unlikely to play any role in mitochondrial tRNA 
processing, since the T domain is the least conserved part of 
mitochondrial tRNAs [30,32,33], a role of the conserved 7 bp 
acceptor stem for mtRNase P processing, although reason- 
able, remains to be established. 
4.2. tRNA processing and mitochondrial disease 
Studies in bacterial tRNA processing have shown that for a 
given tRNA precursor, mutations generally have similar ef- 
fects in vivo as in vitro [34-36]. However, when comparing an 
in vitro analysis of mitochondrial tRNA processing to data 
obtained in vivo, one is inevitably faced with the complexities 
of the mitochondrial genetic system: a mixture of wild-type 
and mutant genomes (heteroplasmy) and variable nuclear ge- 
netic background. These problems can be partially avoided by 
the use of transmitochondrial cybrids [6 8], and this technol- 
ogy has helped to establish the causal relationship of certain 
(mt)tRNA L''"/cUR/ mutations (3243, 3256, 3260, 3271) and the 
pathological mitochondrial phenotype [8-11,14]. 
Steady-state l vels of (mt)tRNA L'''l(UUR/, as well as of the 
flanking 16S rRNA and NDI mRNA, have been investigated 
in three of these mutant cell lines (3243, 3256, 3271) 
[8,14,16,37,38] and in tissue samples of eight MELAS-3243 
patients [39]. While no significant alterations of size and 
amount of these RNAs were detected in cybrids harboring 
the 3243 or 3271 mutation, cell lines as well as patient issues 
(3243) contained increased amounts of unprocessed 
(mt)tRNA r-''''(rU~). Accumulation of this precursor, corre- 
sponding to 16S rRNA-tRNAL~"'(utm/-ND1 mRNA and 
termed RNA 19 [8], was somewhat more pronounced in 
3271 cybrids than in 3243 [16], well in correspondence with 
the difference of the in vitro processing rate (this study). Yet, 
a similar analysis of C to T transition 3256, which has the 
most striking effect on processing in vitro, showed only a very 
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slight increase in the abundance of RNA 19, but significantly 
reduced levels of (mt)tRNA L''''/t~uR) and NDI  mRNA [14]. It 
must, however, be noted that although mutant cybrid clones 
may approach homoplasmy, they generally still show consid- 
erable phenotypic heterogeneity [6,8,14,16]. 
RNA analysis from tissues of the patient with mutation 
3302 is somewhat at odds with our in vitro analysis. While 
this mutation has no marked effect on processing in vitro, 
accumulation of RNA 19 in a tissue specific manner was 
found in this patient [40]. It is currently not possible to resolve 
this discrepancy. No information on mitochondrial RNAs is 
available for the remaining (mt)tRNA L~u(t ~m mutations and 
the damaging effect to mitochondrial function by mutation 
3250, 3251, 3252, 3291, 3302, and 3303, in any case, still 
awaits direct demonstration by use of, e.g. transmitochondrial 
cybrid technology. 
The work presented in this paper demonstrates for the first 
time that certain mutations in the human (mt)tRNA L'~'~(UtTR/ 
gene (3243, 3256, 3260, 3271) interfere directly with the effi- 
cient processing of the tRNA precursor. This may explain the 
aberrant levels of certain RNA species found in the respective 
cybrids. Taken together the findings suggest hat a processing 
deficiency of (mt)tRNA L''~(uu~) is a primary molecular impair- 
ment leading to mitochondrial dysfunction and consequently 
to disease. The implications of a reduced processing efficiency 
for mitochondrial protein biosynthesis are, however, currently 
only poorly understood and represent an area for future re- 
search that may lead to a more complete understanding of the 
molecular pathology of the associated iseases. Mitochondria 
could either be deprived of adequate levels of the affected 
RNAs (16S rRNA, tRNA L''u(u~;R), ND1 mRNA) or the accu- 
mulating precursor (RNA 19) might act in a hitherto un- 
known dominant negative way. In this context it has been 
proposed that unprocessed 16S rRNA (RNA 19) might be 
incorporated into mitochondrial ribosomes and interfere 
with proper mitochondrial translation ('ribosome stalling' 
model) [38,41]. 
In any case, it cannot be excluded that mutations in 
(mt)tRNA L'''~!t:tJm impairing tRNA processing may interfere 
with other mitochondrial functions as well. A transcription 
termination factor binding site is embedded in the 
(mt)tRNA L''''/~TlTm gene [42], and mutation 3243 has been 
shown to dramatically reduce 16S rRNA transcription termi- 
nation in vitro [43,44]. However, no evidence for such an 
impairment has been found in transmitochondrial cybrids 
[8,9] or in vivo [45]. Other mutations within or very close to 
the binding site (3250, 3251, 3252, 3256, 3260, 3271) did fur- 
thermore not alter in vitro termination efficiency [44]. Base 
substitutions could nevertheless conceivably impact on one 
of the other steps in tRNA maturation, stability of the 
tRNA, and/or charging of the tRNA by its cognate amino- 
acyl-tRNA synthetase. 
4.3. The (mt) tRNA L''''cr~t~l hot spot 
Due to the unusually large number of presumably patho- 
genic point mutations in (mt)tRNA L~'u(Uum, its gene has been 
postulated to be an etiologic hot spot [46]. It has furthermore 
been suggested that higher demands on correct sequence in 
this gene reduce the number of potential neutral mutations 
[47]. Alternatively, there might be special constraints on high- 
er order tRNA structure. In this regard (mt)tRNA L~'~(~L~) is
without doubt a highly unusual (mt)tRNA, since unlike other 
(mt)tRNAs it has retained all the structural features typically 
found in bacterial or cytoplasmic tRNAs [18,30]. It could thus 
be more prone to minor structural deviations that interfere 
with processing by enzymes tailored to recognize the broad 
range of (mt)tRNAs. 
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